Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.10
+$0.04 · +1.94%
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Latest quote
$2.10
+$0.04 · +1.94%
After-hours
$2.10
$0.00 · 0.00%
Oct 8, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Day range
Current $2.10
52-week range
Current $2.10
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
52
Mixed
Risk
83
Extreme Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Day range
Current $2.10
52-week range
Current $2.10
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 100K USD | 120K USD | 127K USD | 122K USD | 121K USD |
| Gross profit | −100K USD | −120K USD | −127K USD | −122K USD | −121K USD |
| Research and development | 731K USD | 927K USD | 1.07M USD | 1.29M USD | 1.56M USD |
| Selling, general, and administrative | 1.78M USD | 1.13M USD | 1.73M USD | 1.54M USD | 845K USD |
| Operating expenses | 2.51M USD | 2.06M USD | 2.8M USD | 2.83M USD | 2.4M USD |
| Interest income | 610K USD | 7K USD | 56K USD | 5K USD | 6K USD |
| Interest expense | 2.54M USD | 1.04M USD | 757K USD | 765K USD | 835K USD |
| Depreciation and amortization | 100K USD | 120K USD | 127K USD | 123K USD | 122K USD |
| Operating income | −2.61M USD | −2.06M USD | −2.8M USD | −2.83M USD | −2.4M USD |
| Net income | −4.67M USD | −3.02M USD | −4.4M USD | −6.63M USD | −4.2M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB
Fidelity Nasdaq Composite Index ETFONEQ
Invesco Nasdaq Biotechnology ETFIBBQ
ProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
